127 related articles for article (PubMed ID: 17328232)
1. Drug evaluation: DNA/MVA prime-boost HIV vaccine.
Kent S; De Rose R; Rollman E
Curr Opin Investig Drugs; 2007 Feb; 8(2):159-67. PubMed ID: 17328232
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.
Cebere I; Dorrell L; McShane H; Simmons A; McCormack S; Schmidt C; Smith C; Brooks M; Roberts JE; Darwin SC; Fast PE; Conlon C; Rowland-Jones S; McMichael AJ; Hanke T
Vaccine; 2006 Jan; 24(4):417-25. PubMed ID: 16176847
[TBL] [Abstract][Full Text] [Related]
3. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.
Goonetilleke N; Moore S; Dally L; Winstone N; Cebere I; Mahmoud A; Pinheiro S; Gillespie G; Brown D; Loach V; Roberts J; Guimaraes-Walker A; Hayes P; Loughran K; Smith C; De Bont J; Verlinde C; Vooijs D; Schmidt C; Boaz M; Gilmour J; Fast P; Dorrell L; Hanke T; McMichael AJ
J Virol; 2006 May; 80(10):4717-28. PubMed ID: 16641265
[TBL] [Abstract][Full Text] [Related]
4. Development of a DNA-MVA/HIVA vaccine for Kenya.
Hanke T; McMichael AJ; Mwau M; Wee EG; Ceberej I; Patel S; Sutton J; Tomlinson M; Samuel RV
Vaccine; 2002 May; 20(15):1995-8. PubMed ID: 11983261
[TBL] [Abstract][Full Text] [Related]
5. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
Mwau M; Cebere I; Sutton J; Chikoti P; Winstone N; Wee EG; Beattie T; Chen YH; Dorrell L; McShane H; Schmidt C; Brooks M; Patel S; Roberts J; Conlon C; Rowland-Jones SL; Bwayo JJ; McMichael AJ; Hanke T
J Gen Virol; 2004 Apr; 85(Pt 4):911-919. PubMed ID: 15039533
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
Hanke T; McMichael AJ; Dorrell L
J Gen Virol; 2007 Jan; 88(Pt 1):1-12. PubMed ID: 17170430
[TBL] [Abstract][Full Text] [Related]
7. Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya.
Hanke T; McMichael AJ; Samuel RV; Powell LA; McLoughlin L; Crome SJ; Edlin A
Vaccine; 2002 Nov; 21(1-2):108-14. PubMed ID: 12443668
[TBL] [Abstract][Full Text] [Related]
8. DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime.
Smith JM; Amara RR; Campbell D; Xu Y; Patel M; Sharma S; Butera ST; Ellenberger DL; Yi H; Chennareddi L; Herndon JG; Wyatt LS; Montefiori D; Moss B; McClure HM; Robinson HL
AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1335-47. PubMed ID: 15650426
[TBL] [Abstract][Full Text] [Related]
9. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine.
Hanke T; Barnfield C; Wee EG; Ågren L; Samuel RV; Larke N; Liljeström P
J Gen Virol; 2003 Feb; 84(Pt 2):361-368. PubMed ID: 12560568
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.
Chea LS; Amara RR
Expert Rev Vaccines; 2017 Oct; 16(10):973-985. PubMed ID: 28838267
[TBL] [Abstract][Full Text] [Related]
11. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.
Sandström E; Nilsson C; Hejdeman B; Bråve A; Bratt G; Robb M; Cox J; Vancott T; Marovich M; Stout R; Aboud S; Bakari M; Pallangyo K; Ljungberg K; Moss B; Earl P; Michael N; Birx D; Mhalu F; Wahren B; Biberfeld G;
J Infect Dis; 2008 Nov; 198(10):1482-90. PubMed ID: 18808335
[TBL] [Abstract][Full Text] [Related]
12. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa.
Nkolola JP; Wee EG; Im EJ; Jewell CP; Chen N; Xu XN; McMichael AJ; Hanke T
Gene Ther; 2004 Jul; 11(13):1068-80. PubMed ID: 15164090
[TBL] [Abstract][Full Text] [Related]
13. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
14. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
[TBL] [Abstract][Full Text] [Related]
15. A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants.
Afolabi MO; Ndure J; Drammeh A; Darboe F; Mehedi SR; Rowland-Jones SL; Borthwick N; Black A; Ambler G; John-Stewart GC; Reilly M; Hanke T; Flanagan KL
PLoS One; 2013; 8(10):e78289. PubMed ID: 24205185
[TBL] [Abstract][Full Text] [Related]
16. Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques.
Im EJ; Nkolola JP; di Gleria K; McMichael AJ; Hanke T
Eur J Immunol; 2006 Oct; 36(10):2574-84. PubMed ID: 17013988
[TBL] [Abstract][Full Text] [Related]
17. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
Jaoko W; Nakwagala FN; Anzala O; Manyonyi GO; Birungi J; Nanvubya A; Bashir F; Bhatt K; Ogutu H; Wakasiaka S; Matu L; Waruingi W; Odada J; Oyaro M; Indangasi J; Ndinya-Achola J; Konde C; Mugisha E; Fast P; Schmidt C; Gilmour J; Tarragona T; Smith C; Barin B; Dally L; Johnson B; Muluubya A; Nielsen L; Hayes P; Boaz M; Hughes P; Hanke T; McMichael A; Bwayo J; Kaleebu P
Vaccine; 2008 May; 26(22):2788-95. PubMed ID: 18440674
[TBL] [Abstract][Full Text] [Related]
19. Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine.
Liu J; Wyatt LS; Amara RR; Moss B; Robinson HL
Vaccine; 2006 Apr; 24(16):3332-9. PubMed ID: 16472543
[TBL] [Abstract][Full Text] [Related]
20. A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques.
Wee EG; Patel S; McMichael AJ; Hanke T
J Gen Virol; 2002 Jan; 83(Pt 1):75-80. PubMed ID: 11752703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
